BOUNDLESS BIO INC BOLD
ASignal's systematic analysis rates BOLD as Neutral.
Reflects the latest available analysis · analyzed Oct 30, 2026
The case on BOLD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.90)
- High cash position with $72.63M in cash and no debt
- Current ratio of 9.48x indicates strong liquidity
- MACD histogram is expanding positively, suggesting strengthening momentum
- Price above 20-day moving averages (SMA20 and EMA20)
- Negative operating and free cash flow trends
- Negative return on equity (-67.86%) and return on assets (-32.77%)
- No revenue or earnings growth data available
- Forward P/E of -2.52x indicates unprofitable earnings outlook
- Zero news coverage and no Reddit mentions, suggesting lack of market interest
See the full verdict on BOLD
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BOLD
Most investors never get a second opinion, let alone several. ASignal runs BOLD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.